Intramuscular aripiprazole in the acute management of psychomotor agitation

Pharmacotherapy

Volumn 33, Issue 6, 2013, Pages 603-614

  De Filippis, Sergio ^a,b   Cuomo, Ilaria ^b,c   Lionetto, Luana ^a,c   Janiri, Delfina ^c   Simmaco, Maurizio ^a,c   Caloro, Matteo ^c   De Persis, Simone ^b   Piazzi, Gioia ^d   Simonetti, Alessio ^b,c   Telesforo, C Ludovica ^b,c   Sciarretta, Antonio ^d   Caccia, Federica ^c   Gentile, Giovanna ^a,c   Kotzalidis, Georgios D ^c   Girardi, Paolo ^c,e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Clinica di Cura Neuropsichiatrica Villa von Siebenthal   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Department of Neurosciences   (Italy)

^e Villa Rosa   (Italy)

Author keywords

Acute agitation; Aripiprazole; Bipolar disorder; Intramuscular atypical antipsychotics; Schizophrenia

Indexed keywords

ARIPIPRAZOLE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; RATING SCALE; RESTLESSNESS; SCHIZOPHRENIA; SCORING SYSTEM; SEX DIFFERENCE; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; QUINOLONES; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879577217     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1260     Document Type: Article

References (59)

1. Marder SR. A review of agitation in mental illness: treatment guidelines and current therapies. J Clin Psychiatry 2006;67 (Suppl 10):13-21.
2. Busch KA, Fawcett J, Jacobs DG. Clinical correlates of inpatient suicide. J Clin Psychiatry 2003;64:14-19.
3. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000;43:135-145.
4. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second- generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
5. Boulton DW, Kollia G, Mallikaarjun S, et al. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet 2008;47:475-485.
6. Rais AR, Williams K, Rais T, Singh T, Tamburrino M. Use of intramuscular ziprasidone for the control of acute psychosis or agitation in an inpatient geriatric population: an open-label study. Psychiatry (Edgmont) 2010;7(1):17-24.
7. Wagstaff AJ, Easton J, Scott LJ. Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs 2005;19:147-164.
8. San L, Arranz B, Querejeta I, Barrio S, De la Gándara J, Pérez V. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. Eur Psychiatry 2006;21:539-543.
9. Jangro WC, Preval H, Southard R, Klotz SG, Francis A. Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study. Child Adolesc Psychiatry Ment Health 2009;3:9.
10. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-1411.
11. Kwon JS, Jang JH, Kang DH, et al.Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin Neurosci 2009;63:73-81.
12. Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry 2009;8:16.
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987 ;13:261-276.
14. Lindenmayer J-P, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res 1995;14:229-234.
15. Sanford M, Scott LJ. Intramuscular aripiprazole: a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS Drugs 2008;22:335-352.
16. Montero I, Talavera M, Ruiz I. Clinical trials with a new atypical antipsychotic (Aripiprazole): gender specific information analysis. Women Health 2008;47:39-51.
17. de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005;46:262-273.
18. Huang HC, Liu CH, Lan TH, et al. Detection and quantification of aripiprazole and its metabolite, dehydroaripiprazole, by gas chromatography-mass spectrometry in blood samples of psychiatric patients. J Chromatogr B Analyt Technol Biomed Life Sci 2007;856:57-61.
19. Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, Hiemke C, Remschmidt H, Theisen FM. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit 2008;30:462-466.
20. Hendset M, Hermann M, Lunde H, Refsum H, Molden E. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007;63:1147-1151.
21. Suzuki T, Mihara K, Nakamura A, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 2011;33:21-24.
22. Gründer G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry 2008;165: 988-995.
23. Kirschbaum KM, Müller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2008;9:212-218.
24. Guy W. ECDEU Assessment manual of psychopharmacology - revised (DHEW Publ No ADM 76-338). Rockville, MD: U.S.: Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:218-222.
25. Kay SR, Sevy S. Pyramidical model of schizophrenia. Schizophr Bull 1990;16:537-545.
26. Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med 2003;21:192-198.
27. Caloro M, Lionetto L, Cuomo I, et al. An improved simple LC-MS/MS method for the measurement of serum aripiprazole and its major metabolite. J Pharm Biomed Anal 2012;62: 135-139.
28. McClelland LE, McCubbin JA. Social influence and pain response in women and men. J Behav Med 2008;31:413-420.
29. Salinas JA, Paul GL, Newbill WA. Is paranoid status prognostic of good outcomes? It depends. J Consult Clin Psychol 2002;70:1029-1039.
30. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001;155:128-134.
31. Wright P, Birkett M, David SR, et al. Double-blind, placebocontrolled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-1151.
32. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo- controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-448.
33. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-397.
34. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the shortterm management of agitated psychotic patients. J Clin Psychiatry 2001;62:12-18.
35. Centorrino F, Meyers AL, Ahl J, et al. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder. Hum Psychopharmacol 2007;22:455-462.
36. Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006;188:281-292.
37. Sinyor M, Levitt AJ, Cheung AH, et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 2010;71:270-279.
38. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68:111-119.
39. Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007;27:171-176.
40. Mauri MC, Steinhilber CP, Marino R, et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 2005;20:55-60.
41. Nozawa M, Ohnuma T, Matsubara Y, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 2008;30:35-40.
42. Mauri MC, Volonteri LS, Fiorentini A, Pirola R, Bareggi SR. Two weeks' quetiapine treatment for schizophrenia, druginduced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother 2007;8:2207-2213.
43. Ackenheil M, Bräu H, Burkhart A, Franke A, Pacha W. Antipsychotische Wirksamkeit im Verhaltnis zum Plasmaspiegel von Clozapin [Antipsychotic efficacy in relation to plasma levels of clozapine]. Arzneimittelforschung 1976;26:1156-1158.
44. Bräu H, Burkhart A, Pacha W, Ackenheil M. Beziehungen zwischen Wirkungen und Plasmaspiegeln von Clozapin [Relationships between effects and plasma levels of clozapine]. Arzneimittelforschung 1978;28:1300.
45. Liu HC, Chang WH, Wei FC, Lin SK, Lin SK, Jann MW. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit 1996;18:200-207.
46. Aymard N, Baldacci C, Leyris A, et al. Neuroleptic-resistant schizophrenic patients treated by clozapine: clinical evolution, plasma and red blood cell clozapine and desmethylclozapine levels. Therapie 1997;52:227-232.
47. Bell R, McLaren A, Galanos J, Copolov D. The clinical use of plasma clozapine levels. Aust N Z J Psychiatry 1998;32:567-574.
48. Spina E, Avenoso A, Facciolá G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 2000; 148:83-89.
49. Llorca PM, Lancon C, Disdier B, Farisse J, Sapin C, Auquier P. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. J Psychiatry Neurosci 2002;27:30-37.
50. Lee HS, Tan CH, Khoo YM, et al. Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore- a preliminary report. Br J Clin Pharmacol 1999;47:460-461.
51. Mauri MC, Laini V, Boscati L, et al. Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 2001;16:57-63.
52. Spina E, Avenoso A, Facciolá G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 2001;153:238-243.
53. Chen PS, Yang YK, Su SF, Liao YC, Chang JW, Yeh TL. Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone. Psychiatry Clin Neurosci 2004;58:168-172.
54. Kakihara S, Yoshimura R, Shinkai K, et al. Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005;20:71-78.
55. Wang L, Yu L, Zhang AP, et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol 2007;21:837-842.
56. Lostia AM, Mazzarini L, Pacchiarotti I, et al. Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response. Ther Drug Monit 2009;31:475-481.
57. Nazirizadeh Y, Vogel F, Bader W, et al. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol 2010;66:797-803.
58. Mauri MC, Colasanti A, Rossattini M, et al. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels. Pharmacopsychiatry 2007;40:89-92.
59. Mace S, Taylor D. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 2009; 23:773-780.